奥希替尼治疗后获得性BRAF V600E突变作为耐药机制
本研究从一名接受奥希替尼治疗进展后的患者恶性胸腔积液中收集细胞并培养,通过质谱进行肿瘤基因分型。结果发现该患者进展时出现获得性BRAF V600E突变,源自胸腔积液的细胞对BRAF V600E抑制剂敏感,且对奥希替尼联合治疗更敏感。结论提示BRAF通路是T790M患者对奥希替尼获得性耐药的潜在机制,同时阻断BRAF和EGFR具有显著抑制作用。
要点
- 奥希替尼治疗后进展患者中检出获得性BRAF V600E突变
- 胸腔积液来源细胞对BRAF V600E抑制剂敏感
- 联合阻断BRAF和EGFR对耐药细胞有显著抑制作用
核心结论
- T790M患者对奥希替尼获得性耐药的潜在机制之一是通过BRAF通路。
- 同时阻断BRAF和EGFR具有显著抑制效果。
研究设计与样本
- 在1名接受奥希替尼治疗的患者进展时收集恶性胸腔积液细胞并培养,进行肿瘤基因分型、磷酸化蛋白检测和锚着依赖性集落形成实验。
主要发现
- 该患者在奥希替尼治疗进展时发现获得性BRAF V600E突变。
- 源自恶性胸腔积液的细胞对BRAF V600E抑制剂敏感,且对奥希替尼联合治疗更敏感。
关键数值与推荐
- 采用基质辅助激光解吸电离飞行时间质谱进行肿瘤基因分型。
- 检测了EGFR、AKT、MEK和ERK磷酸化水平。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: AZD9291 (osimertinib) is designed for acquired T790M mutation after first- and second-generation EGFR) tyrosine kinase inhibitors have been used. Some of the resistance mechanisms that present after osimertinib treatment, including a newly acquired EGFR C797S mutation, have been identified. It is unclear, however, whether the bypass pathway is also a mechanism of resistance in patients after osimertinib treatment. METHODS: Cells from malignant pleural effusion were collected and cultured at the time of progression in a patient being treated with osimertinib. Tumor genotyping was done by matrix-assisted laser desorption ionization-time of flight mass spectrometry. EGFR, AKT, MEK, and ERK phosphorylation were determined. An anchorage-dependent colony formation assay was used for drug sensitivity. RESULTS: An acquired mutation, BRAF V600E, was found in the patient at the time of progression while being treated with osimertinib. Cells grown from malignant pleural effusion were sensitive to BRAF V600E inhibitor and were more vulnerable to a combination treatment with osimertinib. CONCLUSIONS: A potential mechanism of acquired resistance to osimertinib in patients with T790M is through the BRAF pathway. Simultaneous blockade of the BRAF and EGFR had a significant inhibitory effect.
引用
- Ho CC, Liao WY, Lin CA, et al. Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib. J Thorac Oncol. 2016. PMID: 27923714. doi:10.1016/j.jtho.2016.11.2231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。